Harbinger Health

Harbinger Health, incubated by Flagship Pioneering and launched in 2021, is developing a novel paradigm for cancer screening focused on detecting the disease before tumors form or symptoms appear. The company's platform integrates AI with proprietary biology to identify early cancer-associated biological programs, with the goal of creating a low-cost, multi-cancer blood test. Led by CEO Ajit Singh, Ph.D., the company is in the pre-clinical/development stage and presented early performance data at ASCO 2025. Harbinger seeks to shift cancer care from reactive treatment to proactive pre-emption, targeting a massive unmet need in oncology diagnostics.

Proprietary platform combining artificial intelligence with insights into the biological programs present at the earliest origins of cancer, aimed at detecting cancer from a blood sample before tumor formation or symptoms.

Harbinger operates in the competitive multi-cancer early detection (MCED) space, competing with companies like Grail (Illumina), Exact Sciences, Freenome, and Thrive Earlier Detection. Many competitors have more advanced clinical data and funding. Harbinger's key differentiation is its focus on detecting biological programs from cancer's origin, potentially earlier than methods relying on circulating tumor DNA.